Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 119

Sort by

Sort Order Select

Journal Articles

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study

Blood (2024) 144 (19): 1993–2001.

https://doi.org/10.1182/blood.2024024657

Published: 2024

Includes: Supplemental data

Journal Articles

Single Cell Genotype-Phenotype Analysis Demonstrates That Post-MPN AML Is Driven By Clonal Evolution and Loss of Transcriptional Heterogeneity within Stem Cell Compartments

Jasmin Straube, Julian Grabek, Leanne Cooper, Rohit Haldar, Caroline McNamara, David M Ross, Andrew Perkins, Megan Bywater, Steven W Lane

Blood (2024) 144 (Supplement 1): 1346.

https://doi.org/10.1182/blood-2024-199841

Published: 2024

Journal Articles

Strong Association between Cancer Gene Variants at Diagnosis, Especially ASXL1 , and Emergence of Kinase Domain Mutation-Driven Resistance in CML Patients Despite Frontline Treatment with More Potent BCR::ABL1 Inhibitors

Naranie Shanmuganathan, Carol Wadham, David T Yeung, Nur Hezrin Shahrin, Adelina Fernandes, Muneeza Maqsood, Chung Hoow Kok, Verity A Saunders, Ilaria Stefania Pagani, Rosalie Kenyon, Ming Lin, David M Ross, Timothy P Hughes, Susan Branford

Blood (2024) 144 (Supplement 1): 991.

https://doi.org/10.1182/blood-2024-199899

Published: 2024

Journal Articles

Hematological Improvement and Other Clinical Benefits of Elritercept As Monotherapy and in Combination with Ruxolitinib in Participants with Myelofibrosis from the Ongoing Phase 2 Restore Trial

Blood (2024) 144 (Supplement 1): 997.

https://doi.org/10.1182/blood-2024-201729

Published: 2024

Journal Articles

Longitudinal Clonal Tracking Reveals That Early and Sensitive Detection of Blood Cancer-Related Gene Variants in Patients with Chronic Myeloid Leukemia Predicts Treatment Failure

Susan Branford, Adelina Fernandes, Carol Wadham, Muneeza Maqsood, Nur Hezrin Shahrin, David M Ross, Agnes S. M. Yong, Ming Lin, Rosalie Kenyon, Dominik Kaczorowski, Verity A Saunders, Ilaria Stefania Pagani, John Toubia, Joe McConnell, David T Yeung, Chung Hoow Kok, Timothy P Hughes, Naranie Shanmuganathan

Blood (2024) 144 (Supplement 1): 996.

https://doi.org/10.1182/blood-2024-198827

Published: 2024

Journal Articles

Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is Rare

Blood (2024) 144 (Supplement 1): 476.

https://doi.org/10.1182/blood-2024-201218

Published: 2024

Journal Articles

Durvalumab and Acalabrutinib for Relapsed/Refractory (r/r) High-Grade B-Cell Lymphoma: MoST15, Open Label Phase II Sub-Study of the Molecular Screening and Therapeutics in Leukaemia and Lymphoma (MoST-LLy) Framework

Danielle N Blunt, Rosemary Harrup, Gerlinda Amor, Helen Christensen, Sarah Finlayson, Frank Lin, David M Ross, Julia Dobbins, Anna Brown, Hamish S Scott, Steven W Lane

Blood (2024) 144 (Supplement 1): 1727.

https://doi.org/10.1182/blood-2024-207463

Published: 2024

Journal Articles

Imatinib-Sensitive Chronic Myeloid Leukaemia Is Associated with mtDNA Mutations and Reduced Oxphos Capacity

Ilaria Stefania Pagani, Vaidehi Krishnan, John Ouyang, Chung How Kok, BeiJun Chen, Elyse C Page, Phuong Dang, Verity A Saunders, Jane James, Kelly Lim, Naranie Shanmuganathan, Susan Branford, Charles Chuah, David T Yeung, Daniel Thomas, Timothy P Hughes, Sin Tiong Ong, David M Ross

Blood (2024) 144 (Supplement 1): 2715.

https://doi.org/10.1182/blood-2024-206591

Published: 2024

Journal Articles

Hematologic Improvement and Fatigue Reduction with Elritercept (KER-050) in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS) with Non-Transfusion Dependent Anemia: New Analyses from an Ongoing Phase 2 Trial

Blood (2024) 144 (Supplement 1): 4591.

https://doi.org/10.1182/blood-2024-208186

Published: 2024

Journal Articles

Modified Delphi Process to Develop Best Practice Recommendations for Myelofibrosis Management in Routine Clinical Practice in the Asia-Pacific Region (The APAC-MF Alliance)

Harinder Gill, Chul Won Choi, Hein Than, Hsin-An Hou, Chul Won Jung, Yok-Lam Kwong, Garret M. K. Leung, Melissa G. M. Ooi, Ponlapat Rojnuckarin, David M. Ross, Lee-Yung Shih, Katsuto Takenaka, Winnie Z. Y. Teo, Keita Kirito

Blood (2024) 144 (Supplement 1): 3678.

https://doi.org/10.1182/blood-2024-201402

Published: 2024

Journal Articles

Dynamic Assessment of RBC-Transfusion Dependency (RBC-TD) Improves the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification of MDS

Thomas Wiseman, Michaela Spooner, Shreyas Khanna, Kevin Hung, Carla Toop, Deepak Singhal, David M Ross, David T Yeung, Anna Brown, Hamish S Scott, Christopher N. Hahn, Daniel Thomas, Chung How Kok, Devendra Hiwase

Blood (2024) 144 (Supplement 1): 3208.

https://doi.org/10.1182/blood-2024-209123

Published: 2024

Journal Articles

High Dose Ascorbate Reduces Interleukin-1 Beta Secretion in TET2 Mutant Monocytes and Demonstrates Excellent Safety and Tolerability in CMML Patients in Combination with Azacitidine

Maha M Kamel, Nirmal Robinson, Monika Kutyna, Kelly Lim, Chloe Thompson-Peach, Steven W Lane, David T Yeung, Agnes S. M. Yong, David M Ross, Devendra Hiwase, Daniel Thomas

Blood (2024) 144 (Supplement 1): 1817.

https://doi.org/10.1182/blood-2024-204177

Published: 2024

Journal Articles

A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Study of Bomedemstat Versus Hydroxyurea in Patients with Essential Thrombocythemia Naïve to Cytoreductive Therapy

Blood (2024) 144 (Supplement 1): 4569.3.

https://doi.org/10.1182/blood-2024-200881

Published: 2024

Journal Articles

CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF Hypersensitivity

Kelly Lim, Monika Kutyna, Winnie Kan, Angel F. Lopez, Anna Brown, Agnes S. M. Yong, Steven W Lane, Chun Yew Fong, Timothy P Hughes, David T Yeung, David M Ross, Devendra Hiwase, Daniel Thomas

Blood (2024) 144 (Supplement 1): 3196.

https://doi.org/10.1182/blood-2024-202682

Published: 2024

Journal Articles

Computational Cytomorphological Analyses Identifies Bone Marrow Erythroblast Proportion As a Biomarker of Treatment-Free Remission in CML

Mikko Purhonen, Mikael Tatun, Kevin Hung, Oda Tafjord, Shady Adnan-Awad, Perttu Koskenvesa, Sanna Siitonen, Kimmo Porkka, Satu Mustjoki, Signe Danielsson, Henrik Hjorth-Hansen, Ulla Olsson-Strömberg, Takashi Kumagai, Shinya Kimura, David M Ross, Oscar E. Brück

Blood (2024) 144 (Supplement 1): 1780.

https://doi.org/10.1182/blood-2024-207253

Published: 2024

Journal Articles

A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis

Blood (2024) 144 (Supplement 1): 6629.

https://doi.org/10.1182/blood-2024-200268

Published: 2024

Journal Articles

Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS)

Blood (2024) 144 (Supplement 1): 1825.

https://doi.org/10.1182/blood-2024-203274

Published: 2024

Journal Articles

Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine

Devendra Hiwase, David M Ross, David T Yeung, Agnes S. M. Yong, Steven W Lane, Anna Brown, Chun Yew Fong, Timothy P Hughes, John Reynolds, Daniel Thomas

Blood (2024) 144 (Supplement 1): 1006.

https://doi.org/10.1182/blood-2024-202867

Published: 2024

Journal Articles

Pathogenic Germline Variants in the DNA Damage Repair Pathway Are Enriched in Patients with Hematologic Malignancies with Prior Exposure to Cytotoxic Therapies Compared to Patients with Multiple Cancers without Prior Exposure

Devendra Hiwase, Zoe Price, Chung How Kok, Monika Kutyna, Deepak Singhal, Naranie Shanmuganathan, Lesley Rawlings, David M Ross, David T Yeung, Anna Brown, Christopher N. Hahn, Lucy Godley, Caner Saygin, Hamish S Scott

Blood (2024) 144 (Supplement 1): 4596.

https://doi.org/10.1182/blood-2024-211795

Published: 2024

Journal Articles

Increased Inflammatory Cytokines in Plasma Are Associated with Sustained Treatment-Free Remission in Chronic Myeloid Leukaemia

Blood (2024) 144 (Supplement 1): 993.

https://doi.org/10.1182/blood-2024-201881

Published: 2024

NARROW

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study

Single Cell Genotype-Phenotype Analysis Demonstrates That Post-MPN AML Is Driven By Clonal Evolution and Loss of Transcriptional Heterogeneity within Stem Cell Compartments

Strong Association between Cancer Gene Variants at Diagnosis, Especially ASXL1 , and Emergence of Kinase Domain Mutation-Driven Resistance in CML Patients Despite Frontline Treatment with More Potent BCR::ABL1 Inhibitors

Hematological Improvement and Other Clinical Benefits of Elritercept As Monotherapy and in Combination with Ruxolitinib in Participants with Myelofibrosis from the Ongoing Phase 2 Restore Trial

Longitudinal Clonal Tracking Reveals That Early and Sensitive Detection of Blood Cancer-Related Gene Variants in Patients with Chronic Myeloid Leukemia Predicts Treatment Failure

Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is Rare

Durvalumab and Acalabrutinib for Relapsed/Refractory (r/r) High-Grade B-Cell Lymphoma: MoST15, Open Label Phase II Sub-Study of the Molecular Screening and Therapeutics in Leukaemia and Lymphoma (MoST-LLy) Framework

Imatinib-Sensitive Chronic Myeloid Leukaemia Is Associated with mtDNA Mutations and Reduced Oxphos Capacity

Hematologic Improvement and Fatigue Reduction with Elritercept (KER-050) in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS) with Non-Transfusion Dependent Anemia: New Analyses from an Ongoing Phase 2 Trial

Modified Delphi Process to Develop Best Practice Recommendations for Myelofibrosis Management in Routine Clinical Practice in the Asia-Pacific Region (The APAC-MF Alliance)

Dynamic Assessment of RBC-Transfusion Dependency (RBC-TD) Improves the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification of MDS

High Dose Ascorbate Reduces Interleukin-1 Beta Secretion in TET2 Mutant Monocytes and Demonstrates Excellent Safety and Tolerability in CMML Patients in Combination with Azacitidine

A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Study of Bomedemstat Versus Hydroxyurea in Patients with Essential Thrombocythemia Naïve to Cytoreductive Therapy

CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF Hypersensitivity

Computational Cytomorphological Analyses Identifies Bone Marrow Erythroblast Proportion As a Biomarker of Treatment-Free Remission in CML

A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis

Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS)

Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine

Pathogenic Germline Variants in the DNA Damage Repair Pathway Are Enriched in Patients with Hematologic Malignancies with Prior Exposure to Cytotoxic Therapies Compared to Patients with Multiple Cancers without Prior Exposure

Increased Inflammatory Cytokines in Plasma Are Associated with Sustained Treatment-Free Remission in Chronic Myeloid Leukaemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only